Montreal, Canada – February 14, 2014 – Theratechnologies Inc. (TSX: TH) announced today that it expects current inventory of
EGRIFTA® (tesamorelin for injection) to be depleted in the coming weeks due to a combination of manufacturing delays and issues observed during the production of new batches of
EGRIFTA® . The depletion of the inventory will result in a shortage of
EGRIFTA® and an eventual stockout. EMD Serono, Inc. has notified the United States Food and Drug Administration about this product shortage.